

Appendix 1 Complete patient management and individual survival for patients with secondary neoplasms of the bladder from each primary malignancy

Prostate													
Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Prostate Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	
1	0	1	Direct	Bone, Lymph	n/a	n/a	n/a	n/a	-	Docetaxel (3 cycles)	21 Gy in three fractions	ADT	654
2	4748	3	Direct	Bone, Lymph nodes	n/a	n/a	70 Gy in 35 fractions	ADT	-	-	-	-	97
3	1693	1	Direct	Bone, Lymph	Open Prostatectomy	n/a	70 Gy in 35 fractions	n/a	-	Docetaxel (6 cycles)	21 Gy in three fractions	ADT	1250
4	0	3	Direct	Lymph, bone	n/a	n/a	n/a	n/a	-	-	-	ADT	259
5	0	2	Direct	Bone, Lymph, Lung	n/a	n/a	n/a	n/a	-	-	21 Gy in three fractions	ADT	632
6	0	4	Direct	Lymph	n/a	n/a	n/a	n/a	-	-	-	ADT	77
7	4388	2	Direct	Lymph	n/a	n/a	70 Gy in 35 fractions	n/a	-	Docetaxel (6 cycles)	-	ADT	1489
8	0	2	Direct	Lymph, bone	n/a	n/a	n/a	n/a	-	Docetaxel (6 cycles)	21 Gy in three fractions	ADT	1407
9	0	1	Direct	Lymph, bone	n/a	n/a	n/a	n/a	-	Docetaxel (6 cycles)	21 Gy in three fractions	ADT	961
10	0	3	Direct	Lymph	n/a	n/a	n/a	n/a	-	-	-	ADT	210
11	948	3	Direct	Lymph, Bone, Lung	n/a	n/a	70 Gy in 35 fractions	ADT	-	-	-	ADT	154
12	0	3	Direct	Lymph, bone, liver	n/a	n/a	n/a	n/a	-	-	-	ADT	114

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary prostate malignancy. ADT- androgen deprivation therapy.

Colorectal														
Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Colorectal Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)	
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other		
1	1342	2	Distant	Lymph, liver	Extended Hemicolectomy	6 cycles adjuvant Oxaliplatin/Capecitabine	-	-	-	-	6 cycles FOLFIRI and Bevacizumab 3 cycles (Cetuximab 1 cycle TAS-102)	-	-	260
2	0	1	Direct	Lymph, lung, liver, peritoneum	-	-	-	-	Anterior resection+ TAH + BSO + cystectomy	FOLFIRI	25 Gy in 5 fractions	bevacizumab	1286	
3	0	1	Direct	Lymph, liver	-	-	-	-	Radical cysto-prostatectomy + hartmans	6 cycles Raltitrexed + Oxaliplatin	-	-	627	
4	0	3	Direct	Lymph, lung, liver, bone	-	-	-	-	-	-	-	-	99	
5	2979	3	Distant	Lymph, lung	Anterior Resection	-	25 Gy in 5 fractions	-	-	-	Raltitrexed, Oxaliplatin 6 cycles	-	-	403
6	321	2	Direct	lymph	Hemicolectomy	FOLFOX 6 cycles	-	-	-	-	FOLFIRI 4 cycles	-	-	341
7	62	2	Direct	Lymph, liver	Hemicolectomy	Oxaliplatin 6 cycles	-	-	-	-	fluorouracil/folinic acid 6 cycles	-	-	543
8	81	2	Direct	Lymph, peritnium, liver	anterior resection + TAH + BSO	Oxaliplatin and Capecitabine 6 cycles	short-course radiotherapy	-	-	-	6 cycles FOLFIRI and Bevacizumab	20 Gy 5 fractions	-	720
9	0	3	Direct	Lymph	-	-	-	-	-	-	-	-	-	84

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary colorectal malignancy. FOLFOX- Folinic acid/Fluorouracil (5FU)/Oxaliplatin, FOLFIRI- Folinic acid/Fluorouracil (5FU)/Irinotecan, TAS-102- Trifluridine/tipiracil. TAH +BSO- Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.

Ovarian													
Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Ovarian Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	
1	0	2	Direct	Lymph, peritoneum, liver	-	-	-	-	TAH+ BSO+ Omentectomy + partial cystectomy	paclitaxel and carboplatin + gemcitabine 4 cycles	-	-	695
2	143	1	Distant	Lymph, peritoneum	TAH + BSO	Carboplatin+ paclitaxel + Avastin 6 cycles	-	-	-	-	-	-	410
3	0	2	Direct	Lymph, peritonium	-	-	-	-	-	Avastin and paclitaxel 1 cycle	-	-	369
4	0	2	Direct	Lymph, lung	-	-	-	-	-	-	-	-	127
5	411	3	Distant	Lymph, lungs, liver	TAH + BSO	carboplatin and docetaxel 6 cycles	-	-	-	-	-	-	81

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary ovarian malignancy. TAH +BSO- Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.

Cervical

Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Cervical Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	
1	241	3	Direct	Lymph, liver	-	Cisplatin 2 cycles	20 Gy 5 fractions	-	-	-	-	-	125
2	324	2	Direct	Lymph, rectum	TAH + BSO	Cisplatin 6 cycles	20 Gy 5 fractions	-	-	Cisplatin +paclitaxel 3 cycle	20 Gy 5 fractions	-	236
3	0	3	Direct	Lymph, rectum	-	-	-	-	-	Cisplatin not tolerated then gemcitabine 1 cycle	20 Gy 5 fractions	-	162
4	0	3	Direct	Lymph, rectum, Liver	-	-	-	-	-	-	-	-	134

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary cervical malignancy. TAH +BSO- Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.

Breast

Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/ extent of disease	Treatment at initial diagnosis of Breast Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)	
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other		
1	1869	1	Distant	Bone, Lymph, Liver, Brain, Lung	Mastectomy	FEC+ paclitaxel 6 cycles	Radiotherapy	trastuzumab	-	-	docetaxel	-	Pertuzumab+ Trastuzumab+	241
2	1211	2	Distant	Lymph, Bone, Liver	Mastectomy	FEC + Docetaxel 6 cycles	Radiotherapy	-	-	-	-	-	Anastrozole	162
3	481	2	Distant	Lymph, Liver, Lung	Mastectomy	FEC + Docetaxel 6 cycles	Radiotherapy	Trastuzumab	-	-	Paclitaxel	-	Trastuzumab	369

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary breast malignancy. FEC- 5 fluorouracil (5FU) Epirubicin, Cyclophosphamide.

Lymphoma

Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Lymphoma				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)	
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other		
1	146	3	hematopoietic	Spleen, Liver	-	-	-	-	-	-	-	-	-	98
2	431	2	hematopoietic	Bone marrow, Lung	-	-	-	-	-	-	-	-	-	145
3	368	2	hematopoietic	Lung, Liver	-	CHOP + Methotrexate	-	-	-	-	-	-	-	278

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary lymphoma. CHOP- Cyclophosphamide, Doxorubicin (Adriamycin), Vincristine (Oncovin), Prednisolone.

Renal

Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Renal Cell Carcinoma				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)	
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other		
1	744	2	Distant	Liver, Lung	Radical Nephrectomy	-	-	-	-	-	-	-	-TKI	326
2	3868	0	Distant	Lung	Radical Nephrectomy	-	-	-	-	-	-	-	TKI	1383

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary renal malignancy. TKI- Tyrosine Kinase Inhibitor.

Gastric

Patient	Time between primary diagnosis and secondary (days)	PS	Method of spread	Other Mets/extent of disease	Treatment at initial diagnosis of Gastric Cancer				Treatment following diagnosis of bladder secondary neoplasm				Survival (Days)	
					Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other	Surgery	Chemotherapy (Number of cycles)	Radiotherapy	Other		
1	0	2	Distant	Liver, Bone	-	-	-	-	-	-	epirubicin, cisplatin, and fluorouracil 1 cycle	-	-	98
2	0	3	Distant	Liver, Peritonium, Lung	-	-	-	-	-	-	-	-	-	31

Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary gastric malignancy.